A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Summary

Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394 at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in compliant participants as long as the study is still ongoing and the participants appear to benefiting from treatment with acceptable safety.

Timeline

Start

2020-06-15

Primary completion

2021-09-30

Completion

2023-06-01

Drugs

Indications